The end-stage cancer patients do not have options for curative therapies, and their function and quality of life is poor, however, 145 patients treated by a pilot therapy of the quercetin showed a positive result in their markers with good safety records.
A non-randomized single-arm Pilot design in which each patient will have either low life expectancy due to the aggressive nature of his/her Tumor or failed the prior chemotherapy and will act as their own control.
In this study, the trial is aiming to show improved quality of life outcome measures and therefore the trial is not tumor type specific. The secondary endpoints are related to surrogates of survival/angiogenesis ( VEGF and CTC), and therefore again not tumor type specific.